• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Gene targeting effects by topo i somerase inhibitors using plasma free DNA in patients with SCLC

Research Project

Project/Area Number 21790780
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeSingle-year Grants
Research Field Respiratory organ internal medicine
Research InstitutionOsaka City University

Principal Investigator

KIMURA Tatsuo  Osaka City University, 大学院・医学研究科, 病院講師 (50382049)

Project Period (FY) 2009 – 2010
Project Status Completed (Fiscal Year 2010)
Budget Amount *help
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Keywords小細胞肺癌 / トポイソメラーゼ阻害剤 / 血漿DNA / イリノテカン / エトポシド / ァムルビシン / 肺癌 / 呼吸器病学 / トポイソメラーゼ
Research Abstract

Lung cancer is the leading cause of cancer death, and approximately 15% of all lung cancer patients have small-cell lung cancer (SCLC). Although second-line chemotherapy can produce tumor regression, the prognosis is poor. Amrubicin hydrochloride (AMR) is a synthetic anthracycline anticancer agent and a potent topoisomerase II inhibitor. With its predictable and manageable toxicities, AMR is one of the most attractive agents for the treatment of chemotherapy- sensitive and -refractory relapsed SCLC. I reviewed the applicability of AMR therapy for patients with SCLC on Clinical Medicine Insights Oncology 2011. These clinical trials, including phase III studies, will clarify the status of AMR in the treatment of SCLC.

Report

(3 results)
  • 2010 Annual Research Report   Final Research Report ( PDF )
  • 2009 Annual Research Report
  • Research Products

    (18 results)

All 2011 2010 2009

All Journal Article (10 results) (of which Peer Reviewed: 10 results) Presentation (8 results)

  • [Journal Article] Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride.2011

    • Author(s)
      Kimura T, Kudoh S, Hirata K.
    • Journal Title

      Clinical Medicine Insights : Oncology 5

      Pages: 23-34

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Soft Tissue Squamous Cell Carcinoma in Chest Wall with an Incomplete Border Sign2011

    • Author(s)
      Kimura T, Kudoh S, Tochino Y, Kodama T, Matsumura S, Hirata K
    • Journal Title

      J Med Cases 2(1)

      Pages: 31-33

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride.2011

    • Author(s)
      Kimura T
    • Journal Title

      Clinical Medicine Insights : Oncology

      Volume: 5 Pages: 23-34

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Soft Tissue Squamous Cell Carcinoma in Chest Wall with an Incomplete Border Sign2011

    • Author(s)
      Kimura T
    • Journal Title

      J Med Cases

      Volume: 2 Pages: 31-33

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs.2010

    • Author(s)
      Tanaka H, Kimura T, Kudoh S, Mitsuoka S, Watanabe T, Suzumura T, Tachibana K, Noguchi M, Yano S, Hirata K.
    • Journal Title

      Int J Cancer. [Epub ahead of print] 掲載確定(Webではすでに掲載済み)

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).2010

    • Author(s)
      Kaneda H, Okamoto I, Kimura T, et al.
    • Journal Title

      J Thorac Oncol. 5

      Pages: 105-109

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs2010

    • Author(s)
      Tanaka H, Kimura T
    • Journal Title

      Int J Cancer

      Volume: (WEB)

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer : results of the West Japan Thoracic Oncology Group trial (WJTOG0401).2010

    • Author(s)
      Kaneda H, Kimura T
    • Journal Title

      J Thorac Oncol.

      Volume: 5 Pages: 105-109

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.2009

    • Author(s)
      Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Kyoh S, Tochino Y, Asai K, Kodama T, Ichimaru Y, Yana T, Hirata K
    • Journal Title

      J Thorac Oncol. 4

      Pages: 371-375

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.2009

    • Author(s)
      Kimura T, Kudoh S, Mitsuoka S, Yoshimura N, Tanaka H, Asai K, Kyoh S, Tochino Y, Umekawa K, Hirata K.
    • Journal Title

      Anticancer Drugs. 20(6)

      Pages: 513-518

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Presentation] Reaction of plasma hepatocyte growth factor by administration EGFR-TKls in lung cancer patients.2010

    • Author(s)
      Tanaka H, Kimura T, Suzumura T, Umekawa K, Nagata M, Mitsuoka S, Kudoh S, Yano S, Hirata K.
    • Organizer
      35th ESMO Congress 2010.
    • Place of Presentation
      ミラノ
    • Year and Date
      2010-10-01
    • Related Report
      2010 Final Research Report
  • [Presentation] Reaction of plasma hepatocyte growth factor by administration EGFR-TKls in lung cancer patients.2010

    • Author(s)
      Tanaka H, Kimura T
    • Organizer
      35th ESMO Congress 2010.
    • Place of Presentation
      ミラノ イタリア
    • Year and Date
      2010-10-01
    • Related Report
      2010 Annual Research Report
  • [Presentation] Comparison of adverse events of erlotinib with those of gefitinib in Japanese patients with NSCLC.2010

    • Author(s)
      Suzumura T, Kudoh S, Kimura T, Umakawa K, Tanaka H, Mitsuoka S, Yoshimura N, Hirata K.
    • Organizer
      ASCO Annual '10Meeting
    • Place of Presentation
      シカゴ
    • Year and Date
      2010-06-01
    • Related Report
      2010 Final Research Report
  • [Presentation] Feasibility study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer.2010

    • Author(s)
      Yoshimura N, Kudoh S, Mitsuoka S, Kimura T, Hirata K.
    • Organizer
      ASCO Annual '10Meeting.
    • Place of Presentation
      シカゴ
    • Year and Date
      2010-06-01
    • Related Report
      2010 Final Research Report
  • [Presentation] Comparison of adverse events of erlotinib with those of gefitinib in Japanese patients with NSCLC.2010

    • Author(s)
      Suzumura T, Kimura T
    • Organizer
      ASCO Annual '10Meeting
    • Place of Presentation
      シカゴ USA
    • Year and Date
      2010-06-01
    • Related Report
      2010 Annual Research Report
  • [Presentation] Feasibility study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer.2010

    • Author(s)
      Yoshimura N, Kimura T
    • Organizer
      ASCO Annual '10Meeting.
    • Place of Presentation
      シカゴ USA
    • Year and Date
      2010-06-01
    • Related Report
      2010 Annual Research Report
  • [Presentation] 再発小細胞肺癌における治療抵抗性症例<refractory relapse>の検討2010

    • Author(s)
      梅川加奈子, 木村達郎, 井尻尚樹, 武田倫子, 小林大起, 白土直子, 鈴村倫弘, 渡辺徹也, 藤本寛樹, 田中秀典, 松村佐恵子, 児玉豊城, 一丸之寿, 光岡茂樹, 浅井一久, 姜成勲, 吉村成夫, 鴨井博, 金澤博, 工藤新三, 平田一人
    • Organizer
      第50回日本呼吸器学会学術講演会
    • Place of Presentation
      京都
    • Year and Date
      2010-04-01
    • Related Report
      2010 Final Research Report
  • [Presentation] Plasma concentration of amrubicinol in gamma phase in patients treated for 3 days with amrubicin and hematological toxicities.2009

    • Author(s)
      Kimura T, Kudoh S, Mitsuoka S, Tanaka H, Kyoh S, Suzumura T, Yoshimura N, Asai K, Tochino Y, Hirata K.
    • Organizer
      ASCO Annual '09Meeting
    • Place of Presentation
      オーランド
    • Year and Date
      2009-05-01
    • Related Report
      2010 Final Research Report

URL: 

Published: 2009-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi